Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
IPO Year: 2018
Exchange: NASDAQ
Website: twistbioscience.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/13/2024 | $60.00 | Outperform | Wolfe Research |
6/4/2024 | $53.00 | Buy | Guggenheim |
1/17/2024 | $25.00 → $45.00 | Neutral → Buy | Goldman |
9/27/2023 | $27.00 | Buy | Berenberg |
1/5/2023 | $33.00 | Sector Outperform | Scotiabank |
1/3/2023 | $28.00 → $36.00 | In-line → Outperform | Evercore ISI |
3/2/2022 | Outperform | Cowen | |
2/7/2022 | $130.00 → $75.00 | Overweight | Barclays |
2/7/2022 | $110.00 → $70.00 | Market Perform | SVB Leerink |
10/15/2021 | Outperform | Cowen |
For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato
144 - Twist Bioscience Corp (0001581280) (Subject)
10-Q - Twist Bioscience Corp (0001581280) (Filer)
8-K - Twist Bioscience Corp (0001581280) (Filer)
SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)
144 - Twist Bioscience Corp (0001581280) (Subject)
S-8 - Twist Bioscience Corp (0001581280) (Filer)
SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)
8-K - Twist Bioscience Corp (0001581280) (Filer)
SCHEDULE 13G - Twist Bioscience Corp (0001581280) (Subject)
10-Q - Twist Bioscience Corp (0001581280) (Filer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
Offer end-to-end workflow from library prep through sequencing Twist to be sole provider of new Trinity™ library prep and target enrichment kits for Element AVITI™ sequencer Joint commercial activities to expand customer access to new NGS tools Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced an expanded collaboration to enable Element's AVITI systems and Trinity flowcells with additional Twist library preparation and target enrichment workflows. This press release features multi
Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday June 3, 2025 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events. About Twist Bioscience Corporation At Twist Bios
As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ:TWST) ("Twist" or the "Company"), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 72,991 equity awards, consisting of 53,600 restricted stock units ("RSUs") and up to 19,379 performance stock units ("PSUs"), to 36 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards were granted under Twist's Amended and Restated Inducement Equity Incentive Plan and related form of restricted stock unit award agreement in accor
New terms provide Twist with key license to long DNA technology and assets Ginkgo to continue ordering from Twist with no purchase minimums Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508352416/en/ Under the terms of the revised three-year $15
Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the second quarter fiscal 2025 ended March 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal second quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its f
Spin out expected to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors Atlas Data Storage, a newly formed company, will focus solely on DNA data storage technology and commercialization, with $155 million in seed financing round including ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capital Partners, Earth Foundry, Rsquared VC, In-Q-Tel (IQT), and other undisclosed investors Varun Mehta, previously founder of Nimble Storage, to serve as CEO of Atlas Data Storage Twist remains focused on serving customers across the life sciences spectrum and expanding rev
Adds to robust offering of NGS tools enabling exome sequencing, whole genome sequencing, RNA sequencing, deep sequencing for liquid biopsy research and MRD, and methylation detection Diverse portfolio of adapter sets now includes industry leading number of unique indexes at 3,072 HT UDI Adapters Enables multiplexing and high throughput sequencing Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced the expanded launch of the Twist High Throughput (HT) Unique Dual Index (UDI) Adapter System to enable multiplexing and sample batching at scale. Indexing is a critical part of the li
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, before the opening of the market on May 5, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor
Collaboration to enable cost-effective end-to-end genotyping across large animal and plant populations Companies to present poster at AGBT-Ag Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Curio Genomics, a pioneer in genomics software, today announced a collaboration to accelerate the adoption of NGS workflows in agricultural genomics (agrigenomics) by offering Twist's FlexPrep™ Ultra-High Throughput (UHT) Library Preparation Kit with Curio's bioinformatics software and data platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/
— Supports Acceleration of Research Across Multiple Industries; Maximizes Budget — Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that, for a limited time, all Twist Express Genes orders placed by academic customers globally will be shipped in as few as four days* without incurring a premium for the rapid turnaround time. "At Twist, we recognize the increasing challenge within colleges, universities and research institutions to securing research funding and appreciate that scientific progress must continue unhindered, as Science Doesn't Stop," said Emily M. Leproust, Ph.D.,